A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)

Supported projects > Supported Project by Private Organizations in Other Countries · 2020

Authors: Nalan Baltacı, Elif Erol, Demet TEREK, Özge ALTUN, Mehmet YALAZ

2020-2022, Supported Project by Private Organizations in Other Countries, R & D Project, Continues